Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 14, 2020
Daily News
January 14, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Japan Ethical Drug Sales Slip 1.1% in November 2019: Crecon
January 14, 2020
- Hisamitsu to Establish Subsidiary in Malaysia in October
January 14, 2020
- Eisai Cancer Drug Halaven Goes on Sale in China
January 14, 2020
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
- Kaken Files Axillary Hyperhidrosis Med in Japan
January 14, 2020
- Healios to Develop Next-Generation Cancer Immunotherapy
January 14, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…